logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line

< Back

Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line

Drugs

Cancer and Palliative Care

October 2021


Tislelizumab in combination with gemcitabine and cisplatin is in clinical development for the treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). NPC is a rare type of cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (the pharynx). It is often difficult to distinguish the symptoms of NPC from less serious conditions and many people do not have any symptoms until the cancer reaches an advanced stage. Therefore, there is a medical need for effective treatments for advanced nasopharyngeal cancer.
Tislelizumab is a protein that has been designed to recognise and block a target called PD-1 found on certain cells of the immune system. Some cancers make a protein that attaches to PD-1 and switches off the immune cells’ ability to attack the cancer. By blocking PD-1, the medicine stops the cancer switching off these immune cells, thereby increasing the immune system’s ability to kill the cancer cells. If licenced, tislelizumab in combination with gemcitabine and cisplatin will provide a first line treatment option for patients with recurrent or metastatic nasopharyngeal cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts